Last reviewed · How we verify
NCT05186493
Laparoscopic Robot-assisted Pelvic Exenteration for Pelvic Primary and Recurrent Cancers
NA trial testing robot-assisted total pelvic exenteration in Locally Advanced Pelvic Cancer That Require Pelvic Exenteration in 40 participants. Currently enrolling.
1 December 2025
Quick facts
| Lead sponsor | Oslo University Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 1 November 2021 |
| Primary completion | 1 December 2025 |
| Estimated completion | 1 December 2030 |
| Sites | 1 location across Norway |
Drugs / interventions tested
- robot-assisted total pelvic exenteration
Conditions studied
- Locally Advanced Pelvic Cancer That Require Pelvic Exenteration — all drugs for Locally Advanced Pelvic Cancer That Require Pelvic Exenteration →
Sponsor
Oslo University Hospital
Who can join
18 and older, any sex, with Locally Advanced Pelvic Cancer That Require Pelvic Exenteration. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Radium Hospital Oslo University Hospital Estimated date of first patient enrolled: 3rd quarter 2021 Anticipated recruitment period: 4 years Estimated date of last patient completed: 4th quarter 2025 Locally advanced pelvic cancer that requires total pelvic exenteration Expected study-specific follow-up period per patient: 5 years according to standard follow-up for this patient group Primary endpoint: R0 resection rate (circumferential resection margin \>1mm) Secondary endpoints: Rate of conversion to open surgery, peri- and postoperative complications, hospital length of stay, wound healing at 3 months follow-up, Quality of Life measured by EORTC Quality of Life Questionnaire C-30 preoperatively, at 3 months and 3 year follow-ups, disease-free survival, overall survival. Diagnosis specific endpoints. Open label observational study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05186493
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Oslo University Hospital trials
Trials by the same sponsor.
- NCT07463885 — Spontaneous vs Controlled Mechanical Ventilation in Acute Hypoxemic Respiratory Failure · NA · not yet recruiting
- NCT07427719 — Retinopathy of Prematurity - Visual Function and Retinal Structure · not yet recruiting
- NCT07403331 — Severe Chronic Neuropathic Pain: A Treatment Bundle, Using Spinal Cord Stimulation and Multidisciplinary Treatment, to R · NA · recruiting
- NCT07449897 — Cholecystectomy With Intraoperative Management of Bile Duct Stones in Norway - the BILNOR Study · recruiting
- NCT06173817 — The Use of Isocapnic Hyperventilation (iHV) for Treatment of Methanol Poisoned Patients · Phase 1 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05186493 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Oslo University Hospital
- Last refreshed: 3 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05186493.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing